Expertise in
13
conditions

Dr. Charles H. Redfern

Internal Medicine
Medical Oncology Associates Of San Diego
3075 Health Center Dr Ste 102, 
San Diego, CA 
Offers Telehealth
Expertise in
13
conditions
Medical Oncology Associates Of San Diego
3075 Health Center Dr Ste 102, 
San Diego, CA 

Overview

Charles Redfern is a primary care provider, practicing in Internal Medicine in San Diego, California.

Dr. Redfern is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Pediatric Low-Grade Glioma (pLGG), Variegate Porphyria, Hereditary Coproporphyria, and Hemochromatosis.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 10 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Hospital Affiliations

Grossmont Hospital
Sharp Coronado Hospital And Hlthcr Ctr
Sharp Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
ATRIO Health
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Medical Oncology Associates of San Diego
3075 Health Center Dr Ste 102, San Diego, CA 92123

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients with Brain Cancer
A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients with Brain Cancer
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Biological
Study Drug: Pritumumab
Study Phase: Phase 1
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First-Line Therapy
An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First-Line Therapy
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

15 Total Publications

A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
Journal: Neuro-oncology advances
Published: October 28, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Arthur F. Kavanaugh
Internal Medicine
Expertise in
19
conditions
Dr. Arthur F. Kavanaugh
Internal Medicine
Before you request

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (7.2 miles away)
800-926-8273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arthur Kavanaugh is a primary care provider, practicing in Internal Medicine in La Jolla, California. Dr. Kavanaugh is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Psoriatic Arthritis, Arthritis, Psoriasis, and Necrosis. Dr. Kavanaugh is currently accepting new patients.

Expertise in
13
conditions
Dr. Bruce L. Zuraw
Internal Medicine
Expertise in
13
conditions
Dr. Bruce L. Zuraw
Internal Medicine

UC San Diego

200 W Arbor Dr, 
San Diego,, CA 
 (4.1 miles away)
858-657-8322
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Zuraw is a primary care provider, practicing in Internal Medicine in San Diego,, California. Dr. Zuraw is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Angioedema, Hereditary Angioedema, Hives, Asthma, and Hormone Replacement Therapy (HRT).

Expertise in
13
conditions
Dr. Fouad J. Moawad
Internal Medicine
Expertise in
13
conditions
Dr. Fouad J. Moawad
Internal Medicine

Scripps Clinic John R. Anderson V Medical Pavilion

9898 Genesee Ave, 
La Jolla, CA 
 (7.5 miles away)
858-824-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fouad Moawad is a primary care provider, practicing in Internal Medicine in La Jolla, California. Dr. Moawad is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Charles H. Redfern

How do I make an appointment with Dr. Charles H. Redfern?

You can book an appointment with Dr. Charles H. Redfern by calling their office at 858-637-7888. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Charles H. Redfern a top-rated expert for Pediatric Low-Grade Glioma (pLGG)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Charles H. Redfern is classified as an Advanced expert for Pediatric Low-Grade Glioma (pLGG), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Charles H. Redfern specialize in?

While Dr. Charles H. Redfern is a Internal Medicine, they have specific expertise in Pediatric Low-Grade Glioma (pLGG), Variegate Porphyria, and Hereditary Coproporphyria. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Charles H. Redfern participate in research or clinical trials?

Yes. Dr. Charles H. Redfern has published 15 articles and abstracts on conditions like Pediatric Low-Grade Glioma (pLGG). You can view a list of Dr. Charles H. Redfern's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Charles H. Redfern accept my insurance?

Dr. Charles H. Redfern accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 858-637-7888 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Redfern's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 78 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile